Literature DB >> 16866021

Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China.

L Yi1, Y H Gu, X L Wang, L Z An, X D Xie, W Shao, L Y Ma, J R Fang, Y D An, F Wang, D L Zhang.   

Abstract

To assess the significance of polymorphisms of the genes for angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2 (ACE2) and urotensin II (UTS2) as risk factors for essential hypertension in two populations from north-western China, we enrolled 198 patients with essential hypertension and 131 healthy controls from the Han population and 120 patients with essential hypertension and 102 healthy controls from the Dongxiang population. Polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism were used to analyse gene polymorphisms. The results provided evidence that genetic variants of UTS2 and ACE2 may play a role in the development of essential hypertension in these populations. Polymorphisms of ACE were not associated with essential hypertension in either population. This is the first report showing that the S89N single-nucleotide polymorphism of the UTS2 gene is associated with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16866021     DOI: 10.1177/147323000603400306

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  28 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

2.  ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects.

Authors:  Na Lu; Yang Yang; Yibo Wang; Yan Liu; Gang Fu; Dongmei Chen; Hui Dai; Xiaohan Fan; Rutai Hui; Yang Zheng
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

3.  The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke.

Authors:  Yan-Hui Wu; Jia-Ying Li; Chi Wang; Li-Mei Zhang; Hong Qiao
Journal:  J Clin Lab Anal       Date:  2016-08-08       Impact factor: 2.352

4.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

5.  Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance.

Authors:  María E Sáez; Tarik Smani; Reposo Ramírez-Lorca; Ignacio Díaz; Manuel Serrano-Ríos; Agustín Ruiz; Antonio Ordoñez
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

Review 6.  Angiotensin-converting enzyme 2 in the brain: properties and future directions.

Authors:  Huijing Xia; Eric Lazartigues
Journal:  J Neurochem       Date:  2008-11-05       Impact factor: 5.372

7.  Urotensin-II system in genetic control of blood pressure and renal function.

Authors:  Radoslaw Debiec; Paraskevi Christofidou; Matthew Denniff; Lisa D Bloomer; Pawel Bogdanski; Lukasz Wojnar; Katarzyna Musialik; Fadi J Charchar; John R Thompson; Dawn Waterworth; Kijoung Song; Peter Vollenweider; Gerard Waeber; Ewa Zukowska-Szczechowska; Nilesh J Samani; David Lambert; Maciej Tomaszewski
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

8.  Lack of Association of ACE2 G8790A Gene Mutation with Essential Hypertension in the Chinese Population: A Meta-Analysis Involving 5260 Subjects.

Authors:  Yan-Yan Li
Journal:  Front Physiol       Date:  2012-09-12       Impact factor: 4.566

9.  The urotensin system is up-regulated in the pre-hypertensive spontaneously hypertensive rat.

Authors:  Ellen J Forty; Nick Ashton
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

Review 10.  From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension.

Authors:  Sheila K Patel; Elena Velkoska; Melanie Freeman; Bryan Wai; Terase F Lancefield; Louise M Burrell
Journal:  Front Physiol       Date:  2014-06-24       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.